
## Radica Z Alicic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4999094/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2032-2045.	4.5	1,600
2	Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children. JAMA Network Open, 2019, 2, e1918169.	5.9	130
3	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. American Journal of Kidney Diseases, 2018, 72, 267-277.	1.9	102
4	Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2018, 25, 181-191.	1.4	91
5	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology, 2021, 17, 227-244.	9.6	87
6	Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes, 2019, 68, 248-257.	0.6	80
7	Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 409-416.	4.5	78
8	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2263-2274.	6.1	59
9	Novel Therapies for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2014, 21, 121-133.	1.4	55
10	Direct and Indirect Effects of Obesity on the Kidney. Advances in Chronic Kidney Disease, 2013, 20, 121-127.	1.4	32
11	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and Its Complications, 2016, 30, 1467-1472.	2.3	23
12	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. Diabetes Spectrum, 2015, 28, 167-174.	1.0	18
13	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2022, 79, 457-479.	1.9	18
14	Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 42-49.	4.4	12
15	Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. American Journal of Nephrology, 2016, 44, 122-129.	3.1	10
16	COVID-19 and Gastrointestinal Tract Symptoms: Recognition, Containment, and Learning From the Past. Mayo Clinic Proceedings, 2020, 95, 2320-2324.	3.0	9
17	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. Advances in Chronic Kidney Disease, 2021, 28, 318-327.	1.4	9
18	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. Current Hypertension Reports, 2007, 9, 393-402.	3.5	8

RADICA Z ALICIC

#	Article	IF	CITATIONS
19	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. US Endocrinology, 2020, 16, 80.	0.3	7
20	Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists. American Journal of Health-System Pharmacy, 2022, 79, e65-e70.	1.0	5
21	Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney. Diabetes, 2021, 70, 1617-1619.	0.6	5
22	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
23	In Reply — Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications. Mayo Clinic Proceedings, 2021, 96, 819-820.	3.0	Ο
24	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0